Dauntless physical dmg4/26/2023 ![]() Octreotide, a somatostatin analog that suppresses excessive growth hormone production from pituitary adenomas, is the mainstay of medical management of acromegaly. ![]() ![]() Food and Drug Administration (FDA) has granted orphan drug designation to DP1038, the company’s investigational new drug, octreotide acetate for intranasal administration, for the treatment of acromegaly.Īcromegaly is most often caused by a benign pituitary adenoma and is characterized by clinical features including enlargement of the hands and feet, facial changes, hypertension, diabetes mellitus and cardiomyopathy. San Diego, Calif., January 30, 2018 – Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics announces that the U.S.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |